'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Dr Reddys Laboratories has increased 11.38% to Rs 8572.1 crore. Sales of Pharmaceutical Services segment has gone down 7.29% to Rs 970.90 crore (accounting for 11.16% of total sales). Sales of Global Generics segment has gone up 9.71% to Rs 7,562.00 crore (accounting for 86.94% of total sales). Sales of Others segment has gone up 678.77% to Rs 165.10 crore (accounting for 1.90% of total sales). Inter-segment sales came down from Rs 265.20 crore to Rs 152.80 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 4.92% to Rs 4,862.70 crore. PBIT of Pharmaceutical Services segment fell 38.94% to Rs 108.20 crore (accounting for 2.23% of total PBIT). PBIT of Global Generics segment rose 3.52% to Rs 4,608.60 crore (accounting...
Pleaselogin & subscribe to view the full report.
More Reports
|
|